While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Drugmakers are growing frustrated with the National Health Service after a clawback tax unexpectedly soared, with ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

The pipeline will run for about 213 kilometres to a $7.4 billion polyethylene plant where construction started last September ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone ...

The scrubbing of clinical trial-related pages is notable because of how it could affect the ways researchers both inside and ...